202 related articles for article (PubMed ID: 23896008)
1. First polymer "ruthenium-cyclopentadienyl" complex as potential anticancer agent.
Valente A; Garcia MH; Marques F; Miao Y; Rousseau C; Zinck P
J Inorg Biochem; 2013 Oct; 127():79-81. PubMed ID: 23896008
[TBL] [Abstract][Full Text] [Related]
2. Polymer "ruthenium-cyclopentadienyl" conjugates - New emerging anti-cancer drugs.
Moreira T; Francisco R; Comsa E; Duban-Deweer S; Labas V; Teixeira-Gomes AP; Combes-Soia L; Marques F; Matos A; Favrelle A; Rousseau C; Zinck P; Falson P; Garcia MH; Preto A; Valente A
Eur J Med Chem; 2019 Apr; 168():373-384. PubMed ID: 30826512
[TBL] [Abstract][Full Text] [Related]
3. New water-soluble ruthenium(II) cytotoxic complex: biological activity and cellular distribution.
Morais TS; Santos FC; Jorge TF; Côrte-Real L; Madeira PJ; Marques F; Robalo MP; Matos A; Santos I; Garcia MH
J Inorg Biochem; 2014 Jan; 130():1-14. PubMed ID: 24145065
[TBL] [Abstract][Full Text] [Related]
4. [RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.
Tomaz AI; Jakusch T; Morais TS; Marques F; de Almeida RF; Mendes F; Enyedy EA; Santos I; Pessoa JC; Kiss T; Garcia MH
J Inorg Biochem; 2012 Dec; 117():261-9. PubMed ID: 22877927
[TBL] [Abstract][Full Text] [Related]
5. Biological activity and cellular uptake of [Ru(η5-C5H5)(PPh3)(Me2bpy)][CF3SO3] complex.
Morais TS; Santos F; Côrte-Real L; Marques F; Robalo MP; Madeira PJ; Garcia MH
J Inorg Biochem; 2013 May; 122():8-17. PubMed ID: 23416310
[TBL] [Abstract][Full Text] [Related]
6. Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity.
Mangiapia G; Vitiello G; Irace C; Santamaria R; Colonna A; Angelico R; Radulescu A; D'Errico G; Montesarchio D; Paduano L
Biomacromolecules; 2013 Aug; 14(8):2549-60. PubMed ID: 23705931
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and anticancer activity of ruthenium-pyrazole complexes.
David S; Perkins RS; Fronczek FR; Kasiri S; Mandal SS; Srivastava RS
J Inorg Biochem; 2012 Jun; 111():33-9. PubMed ID: 22484498
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, structure and biological evaluation of bis salicylaldehyde-4(N)-ethylthiosemicarbazone ruthenium(iii) triphenylphosphine.
Prabhakaran R; Kalaivani P; Jayakumar R; Zeller M; Hunter AD; Renukadevi SV; Ramachandran E; Natarajan K
Metallomics; 2011 Jan; 3(1):42-8. PubMed ID: 21132183
[TBL] [Abstract][Full Text] [Related]
10. A comparative chemical-biological evaluation of titanium(IV) complexes with a salan or cyclopentadienyl ligand.
Schur J; Manna CM; Deally A; Köster RW; Tacke M; Tshuva EY; Ott I
Chem Commun (Camb); 2013 May; 49(42):4785-7. PubMed ID: 23598498
[TBL] [Abstract][Full Text] [Related]
11. Novel "ruthenium cyclopentadienyl"-peptide conjugate complexes against human FGFR(+) breast cancer.
Franco Machado J; Machuqueiro M; Marques F; Robalo MP; Piedade MFM; Garcia MH; Correia JDG; Morais TS
Dalton Trans; 2020 May; 49(18):5974-5987. PubMed ID: 32314752
[TBL] [Abstract][Full Text] [Related]
12. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
[TBL] [Abstract][Full Text] [Related]
13. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
14. From catalysts to bioactive organometallics: do Grubbs catalysts trigger biological effects?
Oehninger L; Alborzinia H; Ludewig S; Baumann K; Wölfl S; Ott I
ChemMedChem; 2011 Dec; 6(12):2142-5. PubMed ID: 21901835
[No Abstract] [Full Text] [Related]
15. A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.
Purkait K; Karmakar S; Bhattacharyya S; Chatterjee S; Dey SK; Mukherjee A
Dalton Trans; 2015 Apr; 44(13):5969-73. PubMed ID: 25742181
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial fragmentation is an important cellular event induced by ruthenium(II) polypyridyl complexes in osteosarcoma cells.
Du Y; Fu X; Li H; Chen B; Guo Y; Su G; Zhang H; Ning F; Lin Y; Mei W; Chen T
ChemMedChem; 2014 Apr; 9(4):714-8. PubMed ID: 24403015
[TBL] [Abstract][Full Text] [Related]
17. Rhodium, iridium, and ruthenium half-sandwich picolinamide complexes as anticancer agents.
Almodares Z; Lucas SJ; Crossley BD; Basri AM; Pask CM; Hebden AJ; Phillips RM; McGowan PC
Inorg Chem; 2014 Jan; 53(2):727-36. PubMed ID: 24397747
[TBL] [Abstract][Full Text] [Related]
18. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative activity of (η
Gozzi M; Schwarze B; Sárosi MB; Lönnecke P; Drača D; Maksimović-Ivanić D; Mijatović S; Hey-Hawkins E
Dalton Trans; 2017 Sep; 46(36):12067-12080. PubMed ID: 28799598
[TBL] [Abstract][Full Text] [Related]
20. Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.
Chow MJ; Licona C; Yuan Qiang Wong D; Pastorin G; Gaiddon C; Ang WH
J Med Chem; 2014 Jul; 57(14):6043-59. PubMed ID: 25023617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
